ATC Group: J07BC01 Hepatitis B, purified antigen

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J07BC01 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J07 Vaccines
3 J07B Viral vaccines
4 J07BC Hepatitis vaccines
5 J07BC01 Hepatitis B, purified antigen

Active ingredients in J07BC01

Active Ingredient

Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer.

Related product monographs

Document Type Information Source  
 ENGERIX-B Suspension for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 FENDRIX Suspension for injection MPI, EU: SmPC European Medicines Agency (EU)
 HBVAXPRO Suspension for injection MPI, EU: SmPC European Medicines Agency (EU)
 HEPLISAV B Solution for injection in pre-filled syringe MPI, EU: SmPC European Medicines Agency (EU)
 RECOMBIVAX HB Suspension for injection MPI, US: SPL/PLR FDA, National Drug Code (US)

United States medicines

Medicines classified under this ATC code globally

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Italy (IT)

Lithuania (LT)

Malta (MT)

Netherlands (NL)

New Zealand (NZ)

Nigeria (NG)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.